Corelease of dopamine and serotonin from striatal dopamine terminals.
Level 5 - mechanism / opinion, no new human data
Preclinical laboratory neurochemistry study (mechanism-based bench research)
PubMed 15820694 · doi:10.1016/j.neuron.2005.02.010
What was done
The authors investigated striatal neurotransmitter handling when extracellular serotonin (5-HT) is elevated—either via exogenous 5-HT application or serotonin transporter inhibition with antidepressants such as fluoxetine. They evaluated 5-HT uptake into dopamine terminals and subsequent neurotransmitter release using immunohistochemistry and fast cyclic voltammetry.
What was found
Elevated extracellular 5-HT engaged the dense striatal dopamine transporters (DATs), causing 5-HT to be taken up into striatal dopamine terminals. Upon stimulation, these dopamine terminals coreleased 5-HT alongside dopamine. The abstract provides qualitative findings without numerical measurements or statistical parameters.
Why it matters
These findings reveal that serotonin transporter-blocking antidepressants can shift 5-HT clearance to dopamine terminals, causing ectopic corelease and altering the spatial and temporal dynamics of striatal monoamine signaling.
Limits
The abstract does not specify the animal species, tissue preparation details, or sample size, and reports no quantitative data or effect sizes. The behavioral relevance and human clinical applicability remain unmeasured in this abstract.
Cited by
- supports A paper in Neuron with John Dani as senior author demonstrated that the dopamine transporter pathway takes serotonin into dopamine terminals in rodents after SSRI administration.